Mike Capaldi has held senior roles in the pharmaceutical and life sciences industry since 1982, both in the UK and the USA. Previous large companies included Ciba Geigy, SmithKline & French and Amersham International where he headed up the Drug Development Services in the USA – later becoming an Executive Vice-President in Nycomed Amersham’s healthcare division. For the last 18 years, Mike has worked in the biotech/technology sector serving as executive director on the Boards of both publically listed and private companies including Core Group plc, Oxford Asymmetry plc, Mindweavers plc, Synaptica Ltd, Scancell plc, Hunter-Fleming Ltd and CMP Therapeutics Ltd (in the latter four companies as CEO). Mike is also currently a non-executive director of Stealthyx Therapeutics, Roslin Cells and Synaptica. He joined Edinburgh BioQuarter as Director in 2010 before founding Sunergos Innovations in October 2015.